Drugs Made In Am Stock Price, News & Analysis
Company Description
Drugs Made In Am (NASDAQ: DMIIR) is a publicly traded company in the Blank Checks sector.
DMIIR stock has declined 43.8% over the past year. Shares last traded at $0.0900.
This page provides a comprehensive overview of DMIIR stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In Am (DMIIR) stock last traded at $0.0900. Over the past 12 months, the stock has lost 43.8%.
Latest News
SEC Filings
Drugs Made In Am has filed 5 recent SEC filings, including 4 Form 8-K, 1 Form 10-K. The most recent filing was submitted on April 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMIIR SEC filings →
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Drugs Made In Am (DMIIR) currently stands at 59.7 thousand shares, up 3.6% from the previous reporting period. Over the past 12 months, short interest has increased by 14826%.
Days to Cover History
Days to cover for Drugs Made In Am (DMIIR) currently stands at 3.3 days, up 230% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 230% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 4.9 days.
DMIIR Company Profile & Sector Positioning
Drugs Made In Am (DMIIR) operates in the Blank Checks sector and is listed on the NASDAQ.